Neurorehabilitation News

Treatment with an oral allosteric modulator was nonsuperior to placebo at 6 weeks in adults with Parkinson’s disease whose symptoms included fall risk and cognitive issues, data from JAMA Neurology show.

The FDA has granted priority review to a Biologics License Application for nipocalimab to treat individuals with generalized myasthenia gravis who are antibody positive, according to the manufacturer.

The average wait time between a referral and neurologist visit was more than a month among older adults, with longer wait times for those with serious neurodegenerative conditions like MS, epilepsy and Parkinson’s disease, new research shows.

A clinical-stage biotechnology company will advance a novel autologous chimeric antigen receptor T-cell therapy that targets the immune checkpoint B7-H3 for diffuse intrinsic pontine glioma, or DIPG, a rare incurable pediatric brain tumor.

Topline results from a phase 2/3 clinical trial showed that an eIF2B agonist to treat ALS failed to meet its primary endpoint of slowing disease progression compared with placebo at week 24.

LOS ANGELES — A wearable, behind-the-ear EEG device is feasible for assessment of sleep patterns in young people with Dravet syndrome, according to a poster presented at the American Epilepsy Society annual meeting.

Topline results from a phase 3 clinical trial showed an investigational gene therapy for young people with spinal muscular atrophy type 2 increased mobility and slowed disease progression, according to a press release from Novartis.

In a newly published paper, the American Academy of Neurology promoted 12 key concepts for patients and providers to successfully promote and maintain brain health.

Healio Neurology looks back at the most popular Q&As with industry and specialty experts from the past year.